ClinicalTrials.Veeva

Menu

Exogenous Surfactant in Very Preterm Neonates in Prevention of Bronchopulmonary Dysplasia (CURDYS)

J

Jean Michel Hascoet

Status and phase

Completed
Phase 4

Conditions

Infant, Premature, Diseases
Respiratory Distress Syndrome, Newborn
Bronchopulmonary Dysplasia

Treatments

Other: Air
Drug: Curosurf

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT01039285
2009-012817-23 (Registry Identifier)
MRU-09-02

Details and patient eligibility

About

Advances in perinatal care have made it possible to improve the survival of the most immature neonates, but at the cost of an increase in the population at risk of developing bronchopulmonary dysplasia (BPD). Measures that have attempted to limit the development of BPD are not always effective, or related to major side effects. The physiopathological factors that are identified in BPD should, in theory, respond to surfactant. Therefore, the use of an exogenous surfactant in neonates presenting with pulmonary disease requiring mechanical ventilation, leading to a significant risk of BPD, should allow earlier extubation and thus promote pulmonary healing and growth.

Enrollment

118 patients

Sex

All

Ages

12 to 16 days old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • any neonate of gestational age less than 33 weeks of amenorrhea still on conventional assisted ventilation or HFOV (High Frequency Oscillatory Ventilation), after 14 ± 2 days of life

Exclusion criteria

  • active infection (CRP > 30 mg/L) not controlled by appropriate antibiotic treatment
  • use of corticosteroids in the postnatal period
  • significant neurological or malformative disease
  • surgical intervention < 72 hours
  • refusal of parental approval

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

118 participants in 2 patient groups, including a placebo group

Surfactant instillation
Experimental group
Description:
2.5 ml/kg of Surfactant will be instilled in the trachea
Treatment:
Drug: Curosurf
Placebo instillation
Placebo Comparator group
Description:
2.5 ml/kg of Air will be instilled in the trachea
Treatment:
Other: Air

Trial contacts and locations

13

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems